| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology, St. Vincent Hospital, Worcester 01604, and Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 01605
The administration of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) at a dose of 0.2% of the diet to male Fischer rats results in the appearance of urinary bladder epithelial lesions progressing from hyperplasia to invasive transitional cell carcinomas. These progressive epithelial alterations have been observed by scanning electron microscopy at 2-week intervals with special attention paid to cells covering the luminal surface. After 2 to 4 weeks of FANFT administration there is mild pleomorphism and moderate swelling of the surface cells giving a cobblestone appearance. The normal pattern of microridges of superficial transitional cells is still present, although occasional cells by 4 weeks of FANFT feeding are covered by small uniform microvilli. By 6 weeks these changes are more extensive and more cells are covered with uniform microvilli. By 8 weeks, cells covered with pleomorphic microvilli are found in discrete foci, and by 10 weeks nodular or papillary lesions are present. The 2- and 4-week lesions regress to normal within 2 to 4 weeks of discontinuing FANFT administration, and the 6- and 8-week lesions regress toward normal in 4 to 6 weeks of being fed control diet. The 6-week lesions have regressed entirely to normal 44 weeks after FANFT was stopped, but the 8-week lesions have progressed to moderate or marked hyperplastic lesions by 42 weeks of control diet with pleomorphic cells covered with pleomorphic microvilli. The results of this study suggest that lesions are reversible up to and including 6 weeks of 0.2% FANFT in the diet, and that, by 8 weeks of 0.2% FANFT, irreversible lesions result which do not revert to normal after 42 weeks of control diet.
1 Presented at the Conference "Early Lesions and the Development of Epithelial Cancer," October 21 to 23, 1975, Bethesda, Md. This study was supported in part by USPHS Grant CA-15945 from the National Cancer Institute through the National Bladder Cancer Project.
This article has been cited by other articles:
![]() |
P. Hu, S. Meyers, F.-X. Liang, F.-M. Deng, B. Kachar, M. L. Zeidel, and T.-T. Sun Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability Am J Physiol Renal Physiol, December 1, 2002; 283(6): F1200 - F1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Ambrosio, G. Borzacchiello, F. Bruno, P. Galati, and F. Roperto Uroplakin Expression in the Urothelial Tumors of Cows Vet. Pathol., November 1, 2001; 38(6): 657 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ogawa, M. St. John, M. L. De Oliveira, L. Arnold, T. Shirai, T.-T. Sun, and S. M. Cohen Comparison of Uroplakin Expression During Urothelial Carcinogenesis Induced by N-Butyl-N-(4-Hydroxybutyl)Nitrosamine in Rats and Mice Toxicol Pathol, November 1, 1999; 27(6): 645 - 651. [Abstract] [PDF] |
||||
![]() |
H. Iwata, S. Yamamoto, Y. Yano, S. Ohtani, and S. Fukushima Dose-Dependent Amplification by L-Ascorbic Acid of NaHCO3 Promotion of Rat Urinary Bladder Carcinogenesis Toxicol Pathol, May 1, 1997; 25(3): 284 - 290. [Abstract] [PDF] |
||||
![]() |
S. Molon-Noblot, C. Boussiquet-Leroux, R. A. Owen, E. Irisarri, G. Durand-Cavagna, C. P. Peter, and P. Duprat Rat Urinary Bladder Hyperplasia Induced by Oral Administration of Carbonic Anhydrase Inhibitors Toxicol Pathol, January 1, 1992; 20(1): 93 - 102. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |